Table 1 Patient and tumor characteristics for all 93 patients
Characteristics | 3DCRT (n = 9) | VMAT (n = 43) | Tomotherapy (n = 41) | P value |
|---|---|---|---|---|
Age in years, median (range) | 48 (34–66) | 62 (38–84) | 63 (34–89) | 0.01 |
Age (years) | ||||
 < 60 | 8 | 20 | 17 | 0.034 |
 ≥ 60 | 1 | 23 | 24 |  |
OTT of RT (days) | ||||
 ≤ 61 | 6 | 21 | 13 | 0.091 |
 > 61 | 3 | 22 | 28 |  |
FIGO stage | ||||
 I | 1 | 10 | 3 | 0.081 |
 II | 4 | 25 | 22 |  |
 III | 1 | 4 | 11 |  |
 IV | 3 | 4 | 5 |  |
T classification | ||||
 T1/T2 | 6 | 35 | 25 | 0.114 |
 T3/T4 | 3 | 8 | 16 |  |
Nodal classification | ||||
 N0 | 2 | 32 | 25 | 0.011 |
 N1 | 7 | 11 | 16 |  |
Histological type | ||||
 Squamous cell carcinoma | 8 | 40 | 39 | 0.607 |
 Adenocarcinoma | 1 | 3 | 1 |  |
 Others | 0 | 0 | 1 |  |
Mean EBRT dose (Gy) | 55.1 | 54.1 | 54.2 | 0.516 |
Mean EQD2 of brachytherapy (Gy) | 28.1 | 29.9 | 29.8 | 0.696 |
EQD2 of Point A (Gy) | ||||
 < 81 | 8 | 27 | 32 | 0.147 |
 ≥ 81 | 1 | 16 | 9 |  |
Pretreatment SCC Ag (ng/mL) | ||||
 ≤ 10 | 4 | 23 | 24 | 0.722 |
 > 10 | 5 | 20 | 17 |  |
Post-treatment SCC Ag (ng/mL) | ||||
 ≤ 1.5 | 8 | 38 | 32 | 0.399 |
 > 1.5 | 1 | 5 | 9 |  |
Median follow-up (months) | 43 | 54 | 52 | 0.123 |